Research Article - Journal of Clinical Ophthalmology (2019) Volume 3, Issue 2
Outcome of the use of topical bevacizumab in treatment of superficial corneal vascularization due to pterygium
Purpose: To evaluate the results of using topical bevacizumab (Avastin) as a treatment of superficial corneal vascularization due to pterygium.
Methods: This study was a prospective interventional study. Total thirty patients were included in this study. All were diagnosed with superficial corneal vascularization due to pterygium. Careful history was taken from all patients and they underwent ophthalmological examination including best corrected visual acuity (BCVA), slit lamp biomicroscopy examination and color photos of the ocular surface (cornea and conjunctiva). They received bevacizumab topical eye drops with a concentration of 0.5 mg/ml four times daily for two weeks. Study appointments were held during weeks 1, 2, 6, 12 and 24. This study was conducted at Zagazig ophthalmology hospital.
Results: There was highly significant difference in the superficial corneal vascularization after one and two weeks. Moderate response increases from the first to the second week (3.3% vs. 56.7% respectively, P<0.001). The BCVA improved in about one third of the studied group (33.3%) and there was no significant difference in the corneal opacity before and after treatment. Only four eyes (4/30; 13.3%) showed decrease in the corneal opacity. No adverse events ascribed to the treatment were noted.
Conclusion: The use of topical bevacizumab eye drops in cases of pterygium with superficial corneal vascularization is safe, well tolerated, associated with mild to moderate regression of superficial corneal vascularization and not associated by any drug related side effects.Author(s): Hesham M Elmazar, Ghada Z Rajab